Investor Relations

Investor Relations Home

Stock Information
Corporate Profile

Foamix Pharmaceuticals is a specialty pharmaceutical company, committed to addressing unmet needs of patients by bringing innovative solutions to the field of dermatology. The company is in late-stage clinical development of two lead products based on the company’s first-in-class topical Minocycline Foam: FMX101, for the treatment of moderate-to-severe acne, and FMX102, for the treatment of impetigo. Having completed Phase II clinical trials of these product candidates, the company expects ... More >>

Recent NewsMore >>
11/28/16Foamix to Host Key Opinion Leader Luncheon for Investors Focused on Dermatology, With a Focus on Acne and RosaceaPrinter Friendly Version
11/28/16Foamix Announces Completion of Patient Enrollment in Phase 3 Acne Trials for Minocycline Foam FMX101Printer Friendly Version
11/15/16Foamix Reports Third Quarter 2016 Financial Results and Provides Business UpdatePrinter Friendly Version
11/10/16Foamix Pharmaceuticals to Present at Jefferies London Healthcare Conference on November 17Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Foamix Pharmaceuticals Ltd posts new information to the site. Just enter your e-mail address and click Submit.